Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Low Intensity Focused Ultrasound for Patients With Fibromyalgia

6 de novembro de 2026 atualizado por: Patrick Finan, PhD, University of Virginia

Early Feasibility Study of Low Intensity Focused Ultrasound Neuromodulation in Patients With Fibromyalgia

The overall goal of this study is to establish the safety and feasibility of low intensity transcranial focused ultrasound (liFU) stimulation for patients with fibromyalgia. We will also attempt to investigate the efficacy of liFU for pain and related symptoms and to compare whether liFU effects differ for people trained in different types of meditation.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

Following informed consent (Session 1), participants will participate in a baseline assessment (Session 2), during which they will receive a full battery of questionnaires, as well as a task-based fMRI and a baseline CT scan (the latter used for brain mapping in preparation of the liFU intervention). They will also be randomized during this session. The study is divided into two phases; in Phase 1 they will undergo four virtual sessions of a meditation intervention (either Savoring Meditation or Slow Breathing Meditation), depending on their group allocation (Session 3 to Session 6). They will then receive another assessment composed of questionnaires and a task-based fMRI (Session 7). In Phase 2 they will receive the liFU intervention (Session 8 to Session 11). At Session 11, they will also receive a post-treatment assessment composed of questionnaires and a task-based fMRI. A follow-up assessment (Session 12) four weeks after their final liFU intervention will be composed of questionnaires.

Tipo de estudo

Intervencional

Inscrição (Estimado)

40

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Claudia Denoue F Postdoctoral Researcher, M.D.
  • Número de telefone: (434)-982-2281
  • E-mail: finanlab@uvahealth.org

Estude backup de contato

  • Nome: Sierra Clark Clinical Research Coordinator
  • Número de telefone: (434)-982-2281
  • E-mail: finanlab@uvahealth.org

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Females aged 18-75 years
  • Physician-confirmed diagnosis of FM according to the 2016 American College of Rheumatology criteria.
  • Willingness and ability to comply with scheduled visits and study procedures

Exclusion Criteria:

  • History of major neurological disorders
  • Current unstable psychiatric disorders or severe current substance use disorders
  • Current prescription opioid use or self -reported use of opioids in the past 30 days prior to enrollment (other medications are allowed, but must be on stable dose for at least 4 weeks)
  • Contraindications to MRI
  • Pregnancy or breastfeeding
  • Current neuromodulation therapy
  • Current meditation practice
  • Current participation in another interventional trial that could confound outcomes
  • Cannot read and speak English
  • Prisoner or cognitively impaired individuals
  • Unwilling or unable to use the internet and/or internet-enabled device to complete study procedures
  • Unable or unwilling to comply with study protocols or otherwise determined by the PI to be able to safely participate in the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Low Intensity Focused Ultrasound + Savoring Meditation (liFU+SM)

In this arm, participants first receive training in Savoring Meditation, a positive affect-focused behavioral intervention designed to enhance positive affect and support chronic pain self-management. Participants complete four 20-minute telehealth training sessions over approximately two weeks delivered by a trained interventionist. After completing the meditation training portion, participants in the liFU + SM arm complete four sessions of low-intensity focused ultrasound targeting the nucleus accumbens during which they actively practice Savoring Meditation concurrent with the sonication.

Outros nomes:
  • liFU + SM
Comparador Ativo: Low Intensity Focused Ultrasound

In the liFU arm, participants first spend 4 telehealth sessions undergoing training in a slow breathing meditation practice. Subsequently, participants complete four in-person liFU treatment sessions over four weeks, with sequential bilateral sonications targeting the nucleus accumbens during each session. In this arm, participants do not engage in any concurrent meditation practice or other behavioral intervention during sonication. Rather, they only receive liFU sonication during those sessions.

Outros nomes:
  • liFU

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Safety of liFU intervention
Prazo: At Session 7 (Week 3), at Sessions 8-11 (Weeks 3-6; immediately before and after each intervention and 24h after each intervention), weekly throughout weeks 7-11 and at Session 12 (Week 11).

Number of treatment-related unexpected adverse events and serious adverse events

At Session 7 (Week 3), at Sessions 8-11 (Weeks 3-6; immediately before and after each intervention and 24h after each intervention), weekly throughout weeks 7-11 and at Session 12 (Week 11).
Study recruitment rate
Prazo: Assessed from screening (Session 1; week -1) to enrollment (Session 2; week 0).

Number of participants enrolled divided by number screened.

Assessed from screening (Session 1; week -1) to enrollment (Session 2; week 0).
Study adherence
Prazo: Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

Number of participants to complete all Phase 1 and Phase 2 intervention sessions

Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).
Study retention
Prazo: Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

Number of enrolled participants retained through the entirety of the study

Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Nucleus accumbens activation
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).

Change in blood-oxygen-level-dependent (BOLD) signal in the nucleus accumbens, measured using functional MRI during a task that pairs meditation with noxious thermal stimulation, relative to rest. Changes will be compared between the liFU + Savoring Meditation and liFU arms.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
Change in nucleus accumbens-ventromedial prefrontal cortex functional connectivity
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).

Change in functional connectivity between the nucleus accumbens (NAc) and ventromedial prefrontal cortex (vmPFC), measured using functional MRI during a task that pairs meditation with noxious thermal stimulation, relative to rest. Changes will be compared between the liFU + Savoring Meditation and liFU arms.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
Clinical pain impact
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in clinical pain impact will be evaluated using the Pain, Enjoyment of life, and General activity (PEG) Scale, which is a hybrid measure of pain severity and pain interference. This scale is comprised of 3 items, each rated on a numerical scale from 0-10. The total score is averaged on a scale from 0-10.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Clinical pain severity
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), Sessions 8-11 (Weeks 3-6; immediately after each intervention and 24h after each intervention), weekly throughout weeks 7-11, and Session 12 (week 11).

Changes in clinical pain severity will be evaluated using the Brief Pain Inventory (BPI). Average pain in the past 24 hours is rated on a scale from 0-10.

Assessed at Session 2 (week 0), Session 7 (week 3), Sessions 8-11 (Weeks 3-6; immediately after each intervention and 24h after each intervention), weekly throughout weeks 7-11, and Session 12 (week 11).
Pain catastrophizing
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in pain catastrophizing will be evaluated using the Pain Catastrophizing Scale (PCS). The PCS is a 13-item scale, each noted on a Likert like scale from 0-4. Total scores are obtained by summing all scores, to obtain a score between 0 and 52.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Fatigue
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in fatigue levels will be evaluated using the Fatigue Severity Scale (FSS). The FSS is a 9-item scale, each noted on a Likert like scale from 1-7. Total scores are obtained by summing all scores, to obtain a score between 0 and 63.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Fibromyalgia Impact
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Fibromyalgia Impact will be assessed using the Fibromyalgia Impact Questionnaire Revised (FIQ-R). The FIQ-R is a 21-item scale where each item is rated on a scale from 0-10 and the overall score is calculated as the addition of all items and then normalized relative to a predefined level of importance for each item. Total scores range from 0-100.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Fibromyalgia Severity
Prazo: Assessed at Session 2 (week 0) and Session 7 (week 3).

Fibromyalgia Severity will be assessed with the Widespread Pain Index (WPI) and the Symptom Severity Scale (SSS). The WPI counts the number of tender points reported and can range from 0 to 19. The SSS assesses 3 items on a Likert-like scale (from 0-3) as well as 3 items on a binary Yes/No scale (Yes=1, No=0). The SSS scale yields a score ranging from 0-12. In total, the WPI-SSS score is calculated by adding the WPI and the SSS score, yielding a final total score ranging from 0-31.

Assessed at Session 2 (week 0) and Session 7 (week 3).
Sleep quality
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Sleep quality will be assessed using the Insomnia Severity Index (ISI) and the Pittsburgh Sleep Quality Index (PSQI). The ISI is a 7-item Likert-like scale (ranging from 0-4). The total score is obtained by adding all item scores, yielding a total possible range of 0-28. The PSQI is a scale comprising of 7 different components, each of which may range from 0-3. The total score is obtained by adding all component scores, yielding a total possible range of 0-21.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Positive Affect
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in Positive Affect will be assessed using the Positive and Negative Affect Schedule - Expanded Form (PANAS-X). The PANAS-X consists of 60 items rated on a Likert-like scale (ranging from 1-5). Total scores are separated as General negative affective scores (ranging 10-50), General Positive Affective Scores (ranging 10-50) and a series of emotional scales with varying ranges.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Hedonic Capacity
Prazo: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item scale where each item is rated on a Likert-like scale ranging from 0-3. Total scores are obtained by adding each item, yielding a total score ranging from 0-42.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Patrick Finan Finan, PhD, Department of Anesthesiology, University of Virginia

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de janeiro de 2027

Conclusão Primária (Estimado)

15 de janeiro de 2029

Conclusão do estudo (Estimado)

1 de abril de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

3 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de novembro de 2026

Primeira postagem (Real)

13 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • HSR 303312

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .